Skip to main content
      RT @MeralElRamahiMD: #ACR21 Abst#0449:
      Ever wish you had a tool to help you predict which PsA pts will progress to radio

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0449: Ever wish you had a tool to help you predict which PsA pts will progress to radiographic damage? ➡️Proteomic approaches identified 103 candidate biomarker peptides related to 69 proteins that can potentially do so! @Rheumnow @uptoTate https://t.co/uUsZlBLTWC
      RT @synovialjoints: There are no MRI imaging difference in axSpA with psoriasis, coliitis or iritis. 240 patients in the

      Dr. Antoni Chan synovialjoints

      4 years ago
      There are no MRI imaging difference in axSpA with psoriasis, coliitis or iritis. 240 patients in the SASPIC study show psoriatic axSpA similar to axSpA associated with iritis or colitis. Supports the umbrella concept of axSpA @RheumNow #ACR21 Abst#0902 https://t.co/VKTUv22hEJ https://t.co/lOL82ceSn9
      RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
      RT @MeralElRamahiMD: #ACR21 Abst#0285
      Calculated 10-yr CV risk ↑ w/in 1st yr of new RA dx in 53 Dutch pts:
      ➤43% had

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0285 Calculated 10-yr CV risk ↑ w/in 1st yr of new RA dx in 53 Dutch pts: ➤43% had intermediate (I) or high (H) morbidity risk ➤76% had I or H mortality risk ◘ avg 57yo, 74%♀, 72% HTN, & 57% HLD *️⃣ Early CV risk assessment critical at RA diagnosis! @Rheumnow
      RT @MeralElRamahiMD: #ACR21 Abst#0452
      ⭐️Total Body PET/CT (TB-PET/CT) as a tool to identify subclinical PsA at the p

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0452 ⭐️Total Body PET/CT (TB-PET/CT) as a tool to identify subclinical PsA at the point of transition from psoriasis (PsO). ➡️Should all pts w/ new dx of PsO have a baseline TB-PET/CT to identify early PsA? #ACRBest @Rheumnow @uptoTate https://t.co/IuxVuJgFSd https://t.co/AIuH9CIucy
      RT @MeralElRamahiMD: #ACR21 Abst#0182
      Does tenderness in non-swollen joints of PsA or RA pts portend inflammation &

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0182 Does tenderness in non-swollen joints of PsA or RA pts portend inflammation & radiographic damage? ⭐️NO, except in early PsA! ➡️Abnormal PDUS associated w/ radiographic progression vs tenderness otherwise #ACRBest @Rheumnow @uptoTate https://t.co/iB1E0SL45e https://t.co/3Q30LeCMH4
      RT @Janetbirdope: Rx of knee OA. A step in the right direction? Many knee #OA studies show that exercise can help pain

      Janet Pope Janetbirdope

      4 years ago
      Rx of knee OA. A step in the right direction? Many knee #OA studies show that exercise can help pain and maybe much more - strengthening, alignment, tone, maybe weight loss. Here is a trial - STEP-KOA to support it. #YearInReview #ACR21 @RheumNow https://t.co/rTZUeZuT1c
      RT @MeralElRamahiMD: #ACR21 Abst#0271
      ➡️Patients 40-75 yo w/ RA dx in the prior 5 yrs have ⬆️ prevalence of subc

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0271 ➡️Patients 40-75 yo w/ RA dx in the prior 5 yrs have ⬆️ prevalence of subclinical athero vs age-matched controls. → Should we consider obtaining a carotid US at time of RA dx & monitor per risk status to help optimize CV risk? @Rheumnow https://t.co/3PpHIRk984 https://t.co/ChRTU7zACk
      ×